Evidence map›Paper›PMID 31793634›Full record

ArticleNeuro-oncology2020

Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.

Chibawanye I Ene, Shannon A Kreuser, Miyeon Jung, Huajia Zhang, Sonali Arora, Kara White Moyes, Frank Szulzewsky, Jason Barber, Patrick J Cimino, Hans-Georg Wirsching and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond.Current issues in molecular biology · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Chibawanye I EneDepartment of Neurological Surgery, University of Washington, Seattle, Washington.
Shannon A KreuserBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington.
Miyeon JungDepartment of Neurological Surgery, University of Washington, Seattle, Washington.
Huajia ZhangHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Sonali AroraHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Kara White MoyesBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington.
Frank SzulzewskyHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jason BarberDepartment of Neurological Surgery, University of Washington, Seattle, Washington.
Patrick J CiminoHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Hans-Georg WirschingHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Anoop PatelDepartment of Neurological Surgery, University of Washington, Seattle, Washington.
Paul KongExperimental Histopathology, Fred Hutchinson Cancer Research Center, Seattle Washington.
Timothy R WoodiwissHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Sharon J DurfyDepartment of Neurological Surgery, University of Washington, Seattle, Washington.
A McGarry HoughtonHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Robert H PierceExperimental Histopathology, Fred Hutchinson Cancer Research Center, Seattle Washington.
Ian F ParneyDepartment of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.
Courtney A CraneDepartment of Neurological Surgery, University of Washington, Seattle, Washington.
Eric C HollandDepartment of Neurological Surgery, University of Washington, Seattle, Washington.
Fred Hutch Cancer Center · USUniversity of Washington · USSeattle Children's Hospital · USMayo Clinic · USUniversity of Zurich · CH

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer TherapyU54CA193461 · NCI · DANA-FARBER CANCER INST · PI MICHOR, FRANZISKA · 2015 to 2020
$11.2M
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterialsR01CA195718 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HOLLAND, ERIC C., HOUGHTON, A MCGARRY · 2016 to 2018
$1.9M
Neurosurgery research training in interdisciplinary neuroscienceR25NS079200 · NINDS · UNIVERSITY OF WASHINGTON · PI OJEMANN, JEFFREY G · 2012 to 2021
$1.2M
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA195718NCI NIH HHS U54 CA193461NINDS NIH HHS R25 NS079200
6 · The paper itself

Abstract

backgroundMost glioblastomas recur near prior radiation treatment sites. Future clinical success will require achieving and optimizing an "abscopal effect," whereby unirradiated neoplastic cells outside treatment sites are recognized and attacked by the immune system. Radiation combined with anti-programmed cell death ligand 1 (PD-L1) demonstrated modest efficacy in phase II human glioblastoma clinical trials, but the mechanism and relevance of the abscopal effect during this response remain unknown.

methodsWe modified an immune-competent, genetically driven mouse glioma model (forced platelet derived growth factor [PDGF] expression + phosphatase and tensin homolog loss) where a portion of the tumor burden is irradiated (PDGF) and another unirradiated luciferase-expressing tumor (PDGF + luciferase) is used as a readout of the abscopal effect following systemic anti-PD-L1 immunotherapy. We assessed relevance of tumor neoepitope during the abscopal response by inducing expression of epidermal growth factor receptor variant III (EGFRvIII) (PDGF + EGFRvIII). Statistical tests were two-sided.

resultsFollowing radiation of one lesion, anti-PD-L1 immunotherapy enhanced the abscopal response to the unirradiated lesion. In PDGF-driven gliomas without tumor neoepitope (PDGF + luciferase, n = 8), the abscopal response occurred via anti-PD-L1 driven, extracellular signal-regulated kinase-mediated, bone marrow-derived macrophage phagocytosis of adjacent unirradiated tumor cells, with modest survival implications (median survival 41 days vs radiation alone 37.5 days, P = 0.03). In PDGF-driven gliomas with tumor neoepitope (PDGF + EGFRvIII, n = 8), anti-PD-L1 enhanced abscopal response was associated with macrophage and T-cell infiltration and increased survival benefit (median survival 36 days vs radiation alone 28 days, P = 0.001).

conclusionOur results indicate that anti-PD-L1 immunotherapy enhances a radiation- induced abscopal response via canonical T-cell activation and direct macrophage activation in glioblastoma.

Indexed as

GlioblastomaGliomaAnimalsB7-H1 AntigenImmunotherapyMacrophagesB7-H1 Antigenabscopal effectglioblastomamacrophagesradiationT cells

Identifiers

PMID31793634
PMCPMC7229244
OpenAlexW2994004185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.